A recent study treated a Korean CHAI disease patient with CTLA4 mimetic, CTLA4-Ig (e.g.. abatacept) and was able to control immune activity and improve patient symptoms.
Un estudo recente tratou un caso dun paciente de CHAI coreano con CTLA4 mimético, CTLA4-Ig (por exemplo, abatacept), e logrou controlar a actividade inmune e mellorar os síntomas do paciente.